Barclays assumed coverage on shares of Amedisys (NASDAQ:AMED – Get Rating) in a report released on Monday, The Fly reports. The firm issued an equal weight rating and a $93.00 target price on the health services provider’s stock.
Other equities analysts also recently issued research reports about the company. Benchmark reiterated a buy rating and set a $120.00 price target on shares of Amedisys in a report on Monday, February 13th. Royal Bank of Canada lowered their price target on Amedisys from $114.00 to $111.00 and set an outperform rating on the stock in a report on Tuesday, February 21st. Credit Suisse Group reiterated an outperform rating and set a $115.00 price target on shares of Amedisys in a report on Monday, February 27th. SVB Leerink reduced their price objective on Amedisys from $96.00 to $85.00 and set a market perform rating for the company in a research report on Thursday, January 5th. Finally, Oppenheimer reduced their price objective on Amedisys from $145.00 to $125.00 and set an outperform rating for the company in a research report on Thursday, January 19th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $119.33.
Amedisys Trading Down 0.7 %
NASDAQ:AMED opened at $82.02 on Monday. The stock’s 50 day moving average price is $90.31 and its 200 day moving average price is $94.85. Amedisys has a 52 week low of $79.30 and a 52 week high of $179.91. The company has a market capitalization of $2.67 billion, a P/E ratio of 22.53, a P/E/G ratio of 2.30 and a beta of 1.04. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.09 and a current ratio of 1.09.
Insider Buying and Selling
In other Amedisys news, insider Michael Paul North sold 5,908 shares of Amedisys stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $86.43, for a total transaction of $510,628.44. Following the completion of the transaction, the insider now directly owns 4,164 shares of the company’s stock, valued at $359,894.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP lifted its holdings in shares of Amedisys by 54.0% during the third quarter. First Trust Advisors LP now owns 182,539 shares of the health services provider’s stock valued at $17,668,000 after acquiring an additional 64,019 shares during the period. Federated Hermes Inc. increased its stake in shares of Amedisys by 9.4% in the second quarter. Federated Hermes Inc. now owns 81,541 shares of the health services provider’s stock valued at $8,572,000 after buying an additional 7,031 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Amedisys by 2.5% in the third quarter. State Board of Administration of Florida Retirement System now owns 39,053 shares of the health services provider’s stock valued at $3,780,000 after buying an additional 970 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Amedisys in the second quarter valued at $412,000. Finally, Assenagon Asset Management S.A. increased its stake in shares of Amedisys by 293.7% in the third quarter. Assenagon Asset Management S.A. now owns 164,328 shares of the health services provider’s stock valued at $15,905,000 after buying an additional 122,588 shares in the last quarter. 96.17% of the stock is owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.